Fidelity SPDR Advertisement
Home > Boards > Free Zone > Health and Sciences > Biotech Values

If the progression assessments for the two metrics

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
DewDiligence Member Profile
Member Level 
Followed By 493
Posts 82,462
Boards Moderated 23
Alias Born 09/05/02
160x600 placeholder
Couche-tard To Buy Pantry For $860 Million
Alimentation Couche-Tard agreed to buy convenience-store chain Pantry for about $860 million, strengthening its position in the southeastern U.S.
More Top Equities Stories Of The Day
Banks Find Niche Helping Firms Defend Against Activists
Repsol to Buy Talisman Energy for $8.3 Billion --Update
BofA Whistleblower to Get Nearly $58 Million--Filing
European Stocks Buffeted by Oil -- 3rd Update
OnDeck Capital Surges Above $20 IPO Price
ADR Shares End Lower; BT Group Shares Trade Actively
Hong Kong Pulls Into Second in IPOs
Chrysler Group Changes Name to Mirror Parent Fiat -- Update
DewDiligence Member Level  Thursday, 05/24/12 02:22:04 PM
Re: jq1234 post# 142539
Post # of 184796 
If the progression assessments for the two metrics are made on the same schedule for every patient, it shouldn’t be possible for PFS to be greater than TTP. A death in between progression assessments ought not to cause a patient to be deleted from the TTP dataset, but rather for TTP to be censored at the time of death.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist